An open-label, prospective pilot study evaluating the effect of adalimumab on endothelial function and on cardiovascular biomarkers in severe chronic plaque psoriasis patients eligible for biologic treatment in Australia
Latest Information Update: 23 Jun 2016
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Biomarker; Pharmacodynamics
Most Recent Events
- 28 May 2013 New trial record